AA amyloidosis: Basic knowledge, unmet needs and future treatments

Swiss Medical Weekly

Volumn 142, Issue MAY, 2012, Pages

  Obici, Laura ^a   Merlini, Giampaolo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

AA amyloidosis; Inflammation; Misfolding disease; Rheumatoid arthritis; Serum amyloid A

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; COLCHICINE; EPRODISATE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; METHOTREXATE; SELENOPROTEIN; SERUM AMYLOID A; SERUM AMYLOID P;

AA AMYLOIDOSIS; AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; AORTA ARCH SYNDROME; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; BLEEDING; CAUCASIAN; CROHN DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DUODENUM BIOPSY; EPIDERMOLYSIS BULLOSA; FAMILIAL MEDITERRANEAN FEVER; GASTROINTESTINAL BIOPSY; GIANT CELL ARTERITIS; HEART FAILURE; HEREDITY; HODGKIN DISEASE; HUMAN; HYDROPHOBICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE LIPODYSTROPHY; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEPROSY; LIVER; MESOTHELIOMA; MICROALBUMINURIA; MORTALITY; MYCOPLASMA ARTHRITIDIS; NEPHROTIC SYNDROME; OBESITY; OSTEOMYELITIS; PARAPLEGIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEINURIA; PULMONARY VASCULITIS; QUALITY OF LIFE; RECTUM BIOPSY; RECURRENT FEVER; RECURRENT INFECTION; REMISSION; RETROSPECTIVE STUDY; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCREENING; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; ARTHRITIS; CHRONIC KIDNEY FAILURE; GENETICS; INFLAMMATION; PATHOPHYSIOLOGY; PROTEOSTASIS DEFICIENCY;

AMYLOIDOSIS; ARTHRITIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PROTEOSTASIS DEFICIENCIES; SERUM AMYLOID A PROTEIN;

EID: 84863481270     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13580     Document Type: Review

References (62)

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924-33.
2. Hazenberg B, Van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis. 2000;59:577-79. (Pubitemid 30617081)
3. Immonen K, Finne P, Gronhagen-Riska C, Petterson T, Klaukka T, Kautiainen H, et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid. 2011;18:25-8.
4. Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid. 2011;18 (Suppl 1):208-10.
5. Girnius S, Dember L, Doros G, Skinner M. The changing face of AA amyloidosis: a single center experience. Amyloid. 2011;18 (Suppl 1):226-8.
6. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struc Biol. 2008;18:771-9.
7. Uversky VN. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010;277:2940-53.
8. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010;277:1348-58.
9. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C. Proteolysis of AA amyloid fibril proteins by matrix metalloproteases-1 -2, and 3. Am J Pathol. 2001;159:561-70. (Pubitemid 32751086)
10. van der Hilst JCH, Yamada T, op den Camp HJM, van der Meer JWM, Drenth JPH, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology. 2008;47:1651-4.
11. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J. 2004;18:1749-51. (Pubitemid 39561672)
12. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, et al. In vivo fragmentation of heparan sulphate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005;102:6473-7. (Pubitemid 40617467)
13. Ma B, Nussinov R. Selective molecular recognition in amyloid growth and transmission and cross-species barriers. J Mol Biol. 2011; doi:10.1016/j.jmb. 2011.11.023.
14. Larsson A, Malmstrom S, Westermark P. Signs of cross-seeding: aortic medin as a trigger for protein AA deposition. Amyloid. 2011;18:229-34.
15. Zhang B, Une Y, Fu X, Yan J, Ge F, Yao J, et al. Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. Proc Natl Acad Sci USA 2008;105:7263-8. (Pubitemid 351754466)
16. Westermark GT, Westermark P. Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583:2685-90.
17. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532-40.
18. Sporanova J, Nystrom SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS One 2008;3:e3308.
19. Dixit R, Gupta R, Dave L, Prasad N, Sharma S. Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis. Lung India. 2009;26:41-5.
20. Stankovic C, Grateau G. Is there any treatment for inflammatory amyloidosis? Joint Bone Spine. 2011;78:7-9.
21. Toledo K, Perez MJ, Espinosa M, Ortega R, Aljama P. Antisynthetase syndrome without myositis secondary to AA amyloidosis: a non-described association. Nefrologia. 2011;31:107-27.
22. Alsina E, Martin M, Panades M, Fernandez E. Renal AA amyloidosis secondary to morbid obesity? Clin Nephrol. 2009;72:312-4.
23. Saha A, Theis JD, Vrana JA, Dubey NK, Batra VV, Sethi S. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant. 2011;26:2407-12.
24. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, et al. Genetic variation in selenoprotein S influences inflammatory response. Nat Genet. 2005;37:1234-41. (Pubitemid 41568706)
25. van der Hilst JCH. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal. 2011;11:641-50.
26. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-71. (Pubitemid 46883770)
27. Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol. 2011;26:1215-2.
28. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology. 2006;45:43-9. (Pubitemid 43033873)
29. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009;61:1435-40.
30. Sato H, Kuroda T, Tanabe N, Ajiro J, Wada Y, Murakami S, et al. Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis. Scand J Rheumatol. 2010;39:33-7.
31. Tishko AN, Lapin SV, Vavilova TV, Totolian AA. Early diagnostics of kidney damage in longstanding rheumatoid arthritis and amyloidosis. Amyloid. 2011;18(Suppl 1):217-20.
32. Immonen K, Helin H, Lehtinen K, Hakala M. The usefulness of subcutaneous fat tissue aspiration biopsy for early confirmation of amyloidosis in patients with active ankylosing spondylitis: comment on the article of van Gameren et al. Arthritis Rheum. 2007;56:2467-8.
33. Picken MM. Amyloidosis-Where are we now and where are we heading? Arch Pathol Lab Med. 2010;134:545-51.
34. Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid. 2011;18:175-6.
35. Westermark P, Stenqvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med. 1973;132:522-3.
36. Van Gameren II, Hazenberg BPC, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54:2015-21. (Pubitemid 43877954)
37. Miyaoka M, Matsui T, Hisabe T, Yano Y, Hirai F, Takaki Y, et al. Clinical and endoscopic features of amyloidosis secondary to Crohn's disease: diagnostic value of duodenal observation and biopsy. Dig Endosc. 2011;23:157-65.
38. Kuroda T, Tanabe N, Kobayashi D, Wada Y, Murakami S, Nakano M, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. Rheumatol Int 2011 e-pub.
39. Yilmaz M, Unsal A, Sokmen M, Harmankaya O, Alkim C, Kabukcuoglu F, et al. Duodenal biopsy for diagnosis of renal involvement in amyloidosis. Clin Nephrol. 2012;77:114-8.
40. Foli A, Palladini G, Caporali R, Verga L, Morbini P, Obici L, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid. 2011;18(Suppl 1):80-2.
41. Sacsaquispe SJ, Antunez-de Mayolo EA, Vicetti R, Delgado WA. Detection of AA-type amyloid protein in labial salivary glands. Med Oral Pat Oral Cir Bucal. 2011;16:e149-52.
42. Soares SM, Fervenza FC, Lager DJ, Gertz MA, Cosio FG, Leung N. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis. 2008;52:1079-83.
43. Linke RP, Oos R, Wiegel NM, Nathrath WB. Classification of amyloidosis: Misdiagnosis by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem. 2006;108:197-208. (Pubitemid 44015876)
44. Schonland S, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119:488-93.
45. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9:108-14. (Pubitemid 34787804)
46. Westermark P, Davey E, Lindbom K, Enqvist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem. 2006;108:209-13. (Pubitemid 44015877)
47. Murphy CL, Wang S, Williams T, Weiss DT, Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48-62. (Pubitemid 44548573)
48. Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid. 2011;18:177-82.
49. Fernandez-Nebro A, Olivé A, Castro MC, Herranz Varela A, Riera E, Irigoyen MV, et al. Long-term TNF-α blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010;123:454-61.
50. Immonen K, Finne P, Hakala M, Kautiainen H, Pettersson T, Gronhagen-Riska C. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases - data from the Finnish national registry for kidney diseases. J Rheum. 2008;35:1334-8. (Pubitemid 352000780)
51. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transpl. 2008;23:941-51.
52. Kuroda T, Tanabe N, Sato H, Ajiro J, Wada Y, Murakami S, et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int. 2006;26:1147-53. (Pubitemid 44450853)
53. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854-8. (Pubitemid 43726787)
54. Ueno T, Takeda K, Nagata M. Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant. 2011; doi:10.1093/ndt/gfr357.
55. Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment. Clin Exp Rheumatol. 2011;850-6.
56. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin 1β in autoinflammatory diseases. Arthritis Rheum. 2011;63:314-24.
57. Stankovic Stojanovic K, Delmas Y, Urena Torres P, Peltier J, Pelle G, Jéru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2011 e-pub ahead of print
58. Kofman T, Grimbert P, Canoui-Poitrine F, Zuber J, Garrigue V, Mousson C, et al. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant. 2011;11:2423-31.
59. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349-60. (Pubitemid 46883769)
60. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis Nature. 2002;417:254-9. (Pubitemid 34534701)
61. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93-7.
62. Kluve-Beckerman B, Hardwick J, Du L, Benson MD, Monia BP, Watt A, et al. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid. 2011;18:136-46.